DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX): $0.40

-0.01 (-2.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DRRX POWR Grades

  • Quality is the dimension where DRRX ranks best; there it ranks ahead of 74.89% of US stocks.
  • The strongest trend for DRRX is in Sentiment, which has been heading up over the past 154 days.
  • DRRX's current lowest rank is in the Momentum metric (where it is better than 10.72% of US stocks).

DRRX Stock Summary

  • DRRX has a higher market value than only 19.88% of US stocks; more precisely, its current market capitalization is $105,271,245.
  • Of note is the ratio of DURECT CORP's sales and general administrative expense to its total operating expenses; just 15.05% of US stocks have a lower such ratio.
  • As for revenue growth, note that DRRX's revenue has grown 323.85% over the past 12 months; that beats the revenue growth of 97.12% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to DURECT CORP are GERN, HYLN, IPSC, EVGN, and OGEN.
  • DRRX's SEC filings can be seen here. And to visit DURECT CORP's official web site, go to www.durect.com.

DRRX Valuation Summary

  • DRRX's price/sales ratio is 4.7; this is 135% higher than that of the median Healthcare stock.
  • DRRX's price/sales ratio has moved down 16.3 over the prior 243 months.

Below are key valuation metrics over time for DRRX.

Stock Date P/S P/B P/E EV/EBIT
DRRX 2022-11-25 4.7 3.1 -3.4 -2.8
DRRX 2022-11-23 4.8 3.2 -3.5 -2.8
DRRX 2022-11-22 4.7 3.1 -3.4 -2.8
DRRX 2022-11-21 4.8 3.2 -3.5 -2.9
DRRX 2022-11-18 4.8 3.2 -3.5 -2.9
DRRX 2022-11-17 4.7 3.2 -3.5 -2.8

DRRX Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -925.28%.
  • The 5 year net cashflow from operations growth rate now stands at 114.28%.
  • Its year over year net cashflow from operations growth rate is now at 12.02%.
DRRX's revenue has moved up $9,240,000 over the prior 70 months.

The table below shows DRRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 23.265 -28.98 -31.872
2022-06-30 13.453 -34.11 -39.378
2022-03-31 13.68 -32.161 -36.973
2021-12-31 13.977 -37.311 -36.265
2021-09-30 5.489 -34.58 -24.897
2021-06-30 6.007 -35.905 -24.252

DRRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DRRX has a Quality Grade of C, ranking ahead of 38.99% of graded US stocks.
  • DRRX's asset turnover comes in at 0.065 -- ranking 305th of 680 Pharmaceutical Products stocks.
  • CCXI, LCI, and BHC are the stocks whose asset turnover ratios are most correlated with DRRX.

The table below shows DRRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.065 1.013 -0.373
2021-03-31 0.353 0.982 0.023
2020-12-31 0.412 0.953 0.031
2020-09-30 0.554 0.889 -0.138
2020-06-30 0.624 0.914 0.013
2020-03-31 0.366 0.850 -0.615

DRRX Price Target

For more insight on analysts targets of DRRX, see our DRRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.50 Average Broker Recommendation 1.33 (Strong Buy)

DRRX Stock Price Chart Interactive Chart >

Price chart for DRRX

DRRX Price/Volume Stats

Current price $0.40 52-week high $1.09
Prev. close $0.41 52-week low $0.36
Day low $0.39 Volume 319,300
Day high $0.43 Avg. volume 674,552
50-day MA $0.52 Dividend yield N/A
200-day MA $0.55 Market Cap 90.89M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.


DRRX Latest News Stream


Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about DURECT CORP that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

DURECT Announces 1-for-10 Reverse Stock Split

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022. Beginning with the opening of trading on December 6, 2022, the Company's common stock will trade on a split-adjusted basis.

Yahoo | November 28, 2022

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 2, 2022

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update.

Yahoo | November 2, 2022

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022.

Yahoo | October 26, 2022

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced the enrollment of more than 200 of the planned 300 patients in its Phase 2b AHFIRM trial. The AHFIRM trial seeks to evaluate larsucosterol's potential to serve as a treatment for severe alcohol-associated hepatitis (AH).

Yahoo | October 6, 2022

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo -30.28%
3-mo -44.44%
6-mo -12.87%
1-year -55.34%
3-year -80.58%
5-year -62.96%
YTD -59.43%
2021 -52.37%
2020 -45.53%
2019 691.67%
2018 -47.83%
2017 -31.34%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.724 seconds.